REG - Novacyt S.A. - AGM Voting

Novacyt SAAnnouncement

28/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250528:nRSb3104Ka&default-theme=true

RNS Number : 3104K  Novacyt S.A.  28 May 2025

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

AGM Voting

 

Paris, France, and Manchester, UK - 28 May 2025 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with
a broad portfolio of integrated technologies and services, will be holding its
Annual General Meeting ("AGM") at 1pm CEST/12pm BST on Thursday, 19 June 2025
at the Hilton Hotel, Charles de Gaulle Airport, 8 Rue de Rome, 93290
Tremblay-en-France, France. As usual, and in accordance with French corporate
law, the AGM comprises both ordinary and extraordinary resolutions. All
materials can be found at www.novacyt.com/investors
(http://www.novacyt.com/investors) .

 

Shareholders are strongly encouraged to submit their votes in advance, in
accordance with the instructions in the Notice of the AGM.

 

Under French law, for the AGM and EGM meetings to be quorate at the first
attempt, shareholders representing at least 20% of the share capital and
voting rights, on ordinary resolutions, and 25% of the share capital and
voting rights, on extraordinary resolutions, must be present, represented or
have voted in advance under the conditions set out below.

 

Shareholders can vote in advance of the AGM by:

 

•      Downloading a copy of the proxy voting form from the
website www.novacyt.com/investors (http://www.novacyt.com/investors) ,
completing it and returning it together with evidence of their shareholding
which must be in the form of a share certificate (attestation), either by post
to the following address: CIC Services Assemblées Générales, 6 avenue de
Provence 75452 Paris Cedex 09, or via email to the following
address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later
than 15 June 2025 inclusive.

 

•      Voting on-line using the Votaccess
portal http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu/)  if securities held on
Euronext Growth are registered with any of the following banks: CIC, Natixis,
Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse
Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank,
Bank of New York or JP Morgan. The Votaccess portal will be open from 28 May
2025 to 18 June 2025 at 2pm BST/3pm CEST.

 

•      Voting on-line via a broker, nominee, bank or authorised
intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are
now using the Broadridge ProxyVote on-line voting portal.

 

Participation in the AGM is confined to shareholders who can prove that their
shares are registered in their name or in the name of the intermediary
registered on their behalf by the second business day prior to the AGM, 16
June 2025 at Midnight, Paris time (12am CEST/11pm BST):

 

•     either in the registered securities accounts kept by the company,
or

 

•     in bearer securities accounts kept by the authorised intermediary.

 

Shareholders wishing to attend the AGM in person may:

 

•     For shareholders whose shares are registered with CIC: present
themselves on the day of the Annual General Meeting, with proof of identity.

 

•     Shareholders whose shares are registered in bearer form: ask the
authorised intermediary who manages their securities account to send them a
proof of shareholding or a letter of representation, evidencing that they hold
shares of Novacyt.

 

Shareholders can also request an admission card in advance (a) from CIC
Services, by post to the following address: CIC Services Assemblées
Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email to the
following address: serviceproxy@cic.fr; or (b) on the secure VOTACCESS
platform accessible via the
website https://www.actionnaire.cic-marketsolutions.eu
(https://www.actionnaire.cic-marketsolutions.eu/) .

 

 

Shareholders who have already voted (through a proxy, via their broker,
nominee, bank, authorised intermediary, Votaccess portal or Broadridge
ProxyVote) will be allowed to attend the AGM but will not be able to vote
twice.

 

Following the meeting, a recording of the AGM will be available on the
Company's website at www.novacyt.com/investors
(http://www.novacyt.com/investors) .

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                             +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries. The Company is listed on the London Stock Exchange's AIM
market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFFFSIEEIDFIE